News
Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...
MarketBeat on MSN12d
Will Hims & Hers Fall Along With Novo Nordisk?
One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. (NYSE: HIMS), not only due to its ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Hims & Hers Health (NYSE:HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s CEO, Andrew Dudum, disclosed the sale of more than $33M worth of company stock ...
Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...
Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...
4don MSN
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in ...
Hims & Hers plans to expand into Canada next year, which is when the patent will expire on semaglutide, and it will sell a generic version of the treatment. In the U.S., Novo has patent ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback